Patients' Approach to Medicines in COVID-19

Abstract

Several different guidelines and therapeutic recommendations have been reported for the treatment of COVID-19 since the announcement of the pandemic. In our study, the attitudes and approaches of patients with a medical indication for COVID-19 who were given drugs towards drug usage were evaluated. We aimed to present our data on the drug usage characteristics of patients to contribute to the literature. A total of 399 patients were included in the study. In the study, 51.1% of the patients were female, and 48.9% were male. The highest number of the patients were in the 18-30 age group (27.6%), the lowest number of the patients were 65 years old or older (9.8%). Twenty-five questions prepared by the researchers were asked to the patients to evaluate "their knowledge and attitudes on drug usage and disease prevention in COVID-19." Of the patients, 75.7% were not smokers. No history of chronic disease was present in 65.5% of the patients. It was determined that no drug was recommended for 9.8% of the patients, and hydroxychloroquine and favipiravir were recommended together in 49.9%. The rate of the use of chloroquine alone was 4.8%, and the rate of using only favipiravir was 32.8%. Eighty-two percent of the patients reported that they regularly used the drugs that were recommended. Among the patients, 11.5% either never used the recommended drugs or did not use them at the recommended dose and time. Of the 46 (11.5%) patients who did not use the prescribed drugs regularly, none died. In other words, improvement was observed in the patients who did not use the drugs that were recommended to them. Our aim in this study was to determine the rate and characteristics of the drugs prescribed by physicians in diagnosed patients. In this cross-sectional sample of Turkey, it was determined that the rate of recommended drug usage was sufficient with the data of the city where the study was carried out.

Keywords

• COVID-19
• drugs
• patients
• hydroxychloroquine
• favipiravir

References

1. Zhu N, Zhang D, Wang W et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-733. DOI: 10.1056/NEJMoa2001017
2. https://www.worldometers.info/coronavirus/
3. Silvano Esposito, Silvana Noviello, Pasquale Pagliano. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Rewiev Infez Med 2020;28(2):198-211.
4. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-1720. DOI: 10.1056/NEJMoa2002032
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 coronavirus in Wuhan, China. Lancet 2020;395:497-506.
6. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Review Eur Rev Med Pharmacol Sci 2020;24(8):4539-4547. doi: 10.26355/eurrev_202004_21038.
7. Peng Y, Tao H, Satyanarayanan SK et al. Comprehensive Summary of the Knowledge on COVID-19 Treatment. Aging Dis 2021;12(1):155-191. doi: 10.14336/AD.2020.1124
8. Polack FP, ThomasSJ, Gurtman A et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. For the C4591001 Clinical Trial Group N Engl J Med 2020;383:2603-2615. DOI: 10.1056/NEJMoa2034577

9. https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html
10. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu. https://covid19.saglik.gov.tr/
11. https://hsgm.saglik.gov.tr/tr/calisansagligi-anasayfa
12. Mohd Zulkifli M, ShamsuddinSH , Sulaiman SA et al. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections. Malays J Med Sci 2020;27(2):165-169.
13. Bilezikian JP, Bikle D, Hewison Met et al. Mechanısms ın Endocrınology: Vitamin D and COVID-19. Eur J Endocrinol 2020;183(5):133-147. doi: 10.1530/EJE-20-0665.
14. Aman F, Masood S. How Nutrition can help to fight against COVID-19 Pandemic Pak J Med Sci 2020;36(S4):121-123. doi: 10.12669/pjms.36.COVID19-S4.2776.
15. William Simonson. Vitamin C and coronavirus. Geriatr Nurs 2020;41(3):331-332. doi: 10.1016/j.gerinurse.2020.05.002. Epub 2020 May 8.
16. Günal Ö, Türe E, Bayburtlu M et al. Evaluation of Patients Diagnosed with COVID-19 in Terms of Risk Factors. Mikrobiyol Bul 2020;54(4):575-582. doi: 10.5578/mb.69811.
17. Zeynep Altın. Elderly People in Covid-19 Outbreak. Tepecik Educate. and Research. Hospital. Magazine 2020;30:49-57 doi:10.5222/terh.2020.93723
18. Uğur Chousein EG, Çörtük M, Cınarka H et al. Is there any effect of smoking status on severity and mortality of hospitalized patients with COVID-19 pneumonia? Tuberk Toraks 2020;68(4):371-378. doi: 10.5578/tt.70352.
19. Tomcsányi J, Tomcsányi K. Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine. Orv Hetil 2020;1:161(17):689-691. doi: 10.1556/650.2020.31817.
20. Ramireddy A, Chugh H, Reinier K et al. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 2020;16:9(12):e017144. doi: 10.1161/JAHA.120.017144. Epub 2020 May 28.
21. Joshi S, Parkar J, Ansari A et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021;102:501-508. doi: 10.1016/j.ijid.2020.10.069. Epub 2020 Oct 30.
22. Peter A McCullough. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). Antimicrob Agents Chemother 2020:17:64(12):e02017-20. doi: 10.1128/AAC.02017-20. Print 2020 Nov 17.
23. https://grip.gov.tr/depo/saglik-calisanlari/ulusal_pandemi_plani.pdf
24. Duygu Zorlu Karayiğit. Have the opinions of the patients about influenza and pneumococcal vaccines influenced by the media? Virtual Congress Proceedings OP-047 2020;10:90-91.Turkish Thoracic Society 23rd Annual Congress 15-18 October 2020
25. Chakraborty C, Sharma AR, Bhattacharya M et al. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. Immune Netw 2021;19;21(1):e5. doi: 10.4110/in.2021.21.e5. eCollection 2021 Feb.
26. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now?. Acta Trop 2021;214:105778. doi: 10.1016/j.actatropica.2020.105778. Epub 2020 Nov 28.
27. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine 2020;29:38(42):6500-6507. doi: 10.1016/j.vaccine.2020.08.043.
28. Detoc M, Bruel S, Frappe P et al. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine 2020;21;38(45):7002-7006. doi: 10.1016/j.vaccine.2020.09.0